** Drug developer Monopar Therapeutics' shares up 13% at $5.25 premarket
** Company signs agreement with AstraZeneca unit Alexion for the license to AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Monopar will be responsible for future global development and drug commercialization activities
** Under deal terms, Monopar will pay Alexion an upfront in cash and equity in Monopar
** As of last close, Monopar stock has more than tripled YTD
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thosmonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。